Appendix 4C – Quarterly Cashflow Report
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 September 2017.
Starpharma receives TGA marketing approval for VivaGel® BV
|
Online financial news portal Finance News Network reported Starpharma received TGA marketing approval for VivaGel® BV, which is expected to be available in pharmacies in the new year under the Fleurstat™ brand. |
VivaGel® BV granted marketing approval in Australia
Starpharma today announced it has received Australian marketing approval from the Therapeutic Goods Administration (TGA) for VivaGel® BV, which is intended for treatment of bacterial vaginosis (BV).
Morgans Under the Microscope Interview featuring Dr Jackie Fairley
Morgans Under the Microscope series featured Starpharma's CEO, Dr Jackie Fairley, discussing a number of key milestones that are approaching and the licensing arrangements entered into with AstraZeneca.
Listen to the podcast (external link).
Shareholder Update October 2017
In this issue:
>> DEP® docetaxel achieves positive phase 1 results and commences phase 2
>> AZ presents first DEP® candidate AZD0466 – a Bcl2/xL inhibitor
>> Successful VivaGel® BV phase 3 results
>> Update on other internal DEP® candidates
>> Grant awarded to Starpharma-Monash
>> Starpharma and Peter Mac Cancer Centre awarded grant
>> FY17 Financial results; >$60M cash at 30 June
>> Annual Report and Annual General Meeting
>> Starpharma News & Events
Download: Shareholder Update October 2017 (pdf file, 1.3mb)
Starpharma and Peter Mac Cancer Centre awarded DEP® Grant
Starpharma and Peter MacCallum Cancer Centre have been awarded a further Federal Government Innovation Connections grant to support innovative research within Starpharma’s DEP® oncology program
AstraZeneca presents first DEP® candidate as Bcl2/xL inhibitor
Starpharma advises that AstraZeneca has this week presented its first DEP® candidate utilising Starpharma’s DEP® delivery platform, AZD0466, at the 3rd AstraZeneca-MedImmune-CRUK Cambridge Centre Symposium 2017 in Cambridge, UK.
Starpharma reports positive phase 1 results
|
Biotech news and industry publication Biotech Dispatch covered the news that Starpharma achieved positive results for its DEP® docetaxel phase 1 clinical trial and will transition immediately into phase 2. |
Starpharma rockets on cancer drug hope
The Herald Sun noted strong investor interest and support for Starpharma regarding its positive phase 1 DEP® docetaxel trial and that no neutropenia was reported in any patients.
DEP® docetaxel positive phase 1 results; phase 2 commences
Starpharma today announced that its phase 1 trial for DEP® docetaxel has achieved the key objective of determining a Recommended Phase 2 Dose (RP2D), with no reports of protocol-defined dose limiting toxicities (DLTs). The trial has now been adapted to transition seamlessly into phase 2, with ethics and regulatory approvals already granted, and recruitment and patient screening activities underway for this next phase.